Search hospitals > Idaho > Twin Falls
Saint Luke's Cancer Institute - Twin Falls
Claim this profileTwin Falls, Idaho 83301
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
251 reported clinical trials
6 medical researchers
Summary
Saint Luke's Cancer Institute - Twin Falls is a medical facility located in Twin Falls, Idaho. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Saint Luke's Cancer Institute - Twin Falls is involved with conducting 251 clinical trials across 442 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
99 reported clinical trials
175 drugs studied
Charles W. DrescherProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Tumors
44 reported clinical trials
85 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
26 reported clinical trials
63 drugs studied
Clinical Trials running at Saint Luke's Cancer Institute - Twin Falls
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Gastric Cancer
Colorectal Cancer
Laryngeal Cancer
Pancreatic Cancer
Multiple Myeloma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Cancer Institute - Twin Falls?
Saint Luke's Cancer Institute - Twin Falls is a medical facility located in Twin Falls, Idaho. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Saint Luke's Cancer Institute - Twin Falls is involved with conducting 251 clinical trials across 442 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.